Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1980 5
1981 2
1982 5
1983 4
1984 3
1985 1
1986 1
1987 1
1988 5
1989 3
1990 2
1991 2
1992 1
1993 2
1994 2
1995 7
1996 4
1997 4
1998 2
1999 4
2000 2
2001 5
2002 3
2003 1
2004 2
2005 7
2006 10
2007 12
2008 10
2009 10
2010 6
2011 5
2012 8
2013 6
2014 6
2015 9
2016 8
2017 5
2018 2
2019 5
2020 4
2021 3
2022 8
2023 2
2024 3
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

192 results

Results by year

Filters applied: . Clear all
Page 1
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT Investigator Study Group. Howard JF Jr, et al. Lancet Neurol. 2021 Jul;20(7):526-536. doi: 10.1016/S1474-4422(21)00159-9. Lancet Neurol. 2021. PMID: 34146511 Clinical Trial.
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.
Howard JF Jr, Bresch S, Genge A, Hewamadduma C, Hinton J, Hussain Y, Juntas-Morales R, Kaminski HJ, Maniaol A, Mantegazza R, Masuda M, Sivakumar K, Śmiłowski M, Utsugisawa K, Vu T, Weiss MD, Zajda M, Boroojerdi B, Brock M, de la Borderie G, Duda PW, Lowcock R, Vanderkelen M, Leite MI; RAISE Study Team. Howard JF Jr, et al. Lancet Neurol. 2023 May;22(5):395-406. doi: 10.1016/S1474-4422(23)00080-7. Lancet Neurol. 2023. PMID: 37059508 Clinical Trial.
Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Benatar M, Hansen T, Rom D, Geist MA, Blaettler T, Camu W, Kuzma-Kozakiewicz M, van den Berg LH, Morales RJ, Chio A, Andersen PM, Pradat PF, Lange D, Van Damme P, Mora G, Grudniak M, Elliott M, Petri S, Olney N, Ladha S, Goyal NA, Meyer T, Hanna MG, Quinn C, Genge A, Zinman L, Jabari D, Shoesmith C, Ludolph AC, Neuwirth C, Nations S, Shefner JM, Turner MR, Wuu J, Bennett R, Dang H, Sundgreen C; ORARIALS-01 trial team. Benatar M, et al. Lancet Neurol. 2024 Jul;23(7):687-699. doi: 10.1016/S1474-4422(24)00134-0. Epub 2024 May 20. Lancet Neurol. 2024. PMID: 38782015 Clinical Trial.
Pseudomonas corneoscleritis.
Alfonso E, Kenyon KR, Ormerod LD, Stevens R, Wagoner MD, Albert DM. Alfonso E, et al. Among authors: wagoner md. Am J Ophthalmol. 1987 Jan 15;103(1):90-8. doi: 10.1016/s0002-9394(14)74175-3. Am J Ophthalmol. 1987. PMID: 3541633
Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial.
Machado PM, McDermott MP, Blaettler T, Sundgreen C, Amato AA, Ciafaloni E, Freimer M, Gibson SB, Jones SM, Levine TD, Lloyd TE, Mozaffar T, Shaibani AI, Wicklund M, Rosholm A, Carstensen TD, Bonefeld K, Jørgensen AN, Phonekeo K, Heim AJ, Herbelin L, Barohn RJ, Hanna MG, Dimachkie MM; Arimoclomol in IBM Investigator Team of the Neuromuscular Study Group. Machado PM, et al. Lancet Neurol. 2023 Oct;22(10):900-911. doi: 10.1016/S1474-4422(23)00275-2. Lancet Neurol. 2023. PMID: 37739573 Free article. Clinical Trial.
Glaucoma-associated corneal endothelial cell damage: A review.
Janson BJ, Alward WL, Kwon YH, Bettis DI, Fingert JH, Provencher LM, Goins KM, Wagoner MD, Greiner MA. Janson BJ, et al. Among authors: wagoner md. Surv Ophthalmol. 2018 Jul-Aug;63(4):500-506. doi: 10.1016/j.survophthal.2017.11.002. Epub 2017 Nov 14. Surv Ophthalmol. 2018. PMID: 29146208 Review.
Corneal intraepithelial neoplasia.
Cameron JA, Wagoner MD. Cameron JA, et al. Among authors: wagoner md. Can J Ophthalmol. 1997 Dec;32(7):471-4. Can J Ophthalmol. 1997. PMID: 9435981 No abstract available.
Trichophyton fungal keratitis.
Mohammad A, Al-Rajhi A, Wagoner MD. Mohammad A, et al. Among authors: wagoner md. Cornea. 2006 Jan;25(1):118-22. doi: 10.1097/01.ico.0000164834.77291.51. Cornea. 2006. PMID: 16331054
Towards better models and mechanistic biomarkers for drug-induced gastrointestinal injury.
Carr DF, Ayehunie S, Davies A, Duckworth CA, French S, Hall N, Hussain S, Mellor HR, Norris A, Park BK, Penrose A, Pritchard DM, Probert CS, Ramaiah S, Sadler C, Schmitt M, Shaw A, Sidaway JE, Vries RG, Wagoner M, Pirmohamed M. Carr DF, et al. Among authors: wagoner m. Pharmacol Ther. 2017 Apr;172:181-194. doi: 10.1016/j.pharmthera.2017.01.002. Epub 2017 Jan 27. Pharmacol Ther. 2017. PMID: 28132905 Review.
Movin' on up: the role of PtdIns(4,5)P(2) in cell migration.
Ling K, Schill NJ, Wagoner MP, Sun Y, Anderson RA. Ling K, et al. Among authors: wagoner mp. Trends Cell Biol. 2006 Jun;16(6):276-84. doi: 10.1016/j.tcb.2006.03.007. Epub 2006 Apr 17. Trends Cell Biol. 2006. PMID: 16616849 Review.
192 results